Baylis Medical Company, Inc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Baylis Medical Company, Inc
Restructuring Edition: OrbiMed/Foresite and Concentra responded quickly after Theseus implemented a 72% workforce reduction and began a search for strategic alternatives despite having $225.4m in cash. REGENXBIO, Novavax and Lyell also revealed job cuts despite large cash stockpiles.
Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
- Medical Devices
- Diagnostic Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
- Implantable Devices
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- CNP Therapeutics
- Fralex Therapeutics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.